HER2-Positive Metastatic Breast Cancer
Carlos Arteaga, MD

I. Background

• The 5-year and 10-year survival rates for metastatic breast cancer (mBC) are 26% and 5% to 10%, respectively (Clements et al, 2012; American Cancer Society, 2016).

• For the 20% to 25% of patients with tumors that overexpress human epidermal growth factor receptor-2 (HER2), the disease course is more aggressive and associated with shorter survival times (Prat and Baselga, 2008).

• The advent of HER2-targeted therapies has dramatically improved patient outcomes in HER2-positive breast cancer (Santa-Maria et al, 2016); nevertheless, mBC eventually progresses.

• New molecular targets that can evade resistance mechanisms to HER2-directed therapies are being investigated in multiple ongoing trials.

II. Approved and Emerging Agents

A. Anti-HER2 Agents

• Trastuzumab, the first agent approved for the treatment of HER2+ BC, is a recombinant humanized monoclonal antibody that inhibits ligand-independent HER2 and HER3 signaling and also triggers antibody-dependent cellular cytotoxicity.

  – Trastuzumab was approved in 2006 as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant treatment of women with node-positive, HER2-overexpressing BC.

  – The most important adverse event in the metastatic setting was cardiac dysfunction, which occurred in 27% of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8% of the group given an anthracycline and cyclophosphamide alone; 13% of the group given paclitaxel and trastuzumab; and 1% of the group given paclitaxel alone (Slamon et al, 2001).

• Pertuzumab, a humanized monoclonal antibody that inhibits ligand-dependent signaling induced by HER2-HER3 dimers, was approved in 2012 in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ mBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

  – The most common (>30%) AEs in patients who received pertuzumab plus trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy (Baselga et al, 2012).

  • ONT-380 is a small molecule inhibitor of HER2 that has been evaluated in a small phase 1b study in combination with capecitabine and/or trastuzumab following prior treatment with trastuzumab and ado-trastuzumab emtansine (T-DM1) (Hamilton et al, 2015).

    – From 8 patients, 4 partial responses, 2 stable disease, and 2 progressive disease were reported.

    – Most toxicities were Grade 1 or 2, the most common being nausea, vomiting, diarrhea, palmar-plantar erythrodysesthesia, and fatigue.

    – A randomized, placebo-controlled, phase 2 trial is evaluating ONT-380 in combination with trastuzumab and capecitabine in heavily pretreated patients with HER2-positive mBC with or without brain metastases (NCT02614794).

B. EGFR Tyrosine Kinase Inhibitors (TKI)

• In 2007, lapatinib, a small-molecule inhibitor of HER1/EGFR and HER2 tyrosine kinases, was approved for use in combination with capecitabine for the treatment of patients with HER2+ advanced/metastatic breast cancer and who have received prior therapy including an anthracycline, a taxane and trastuzumab.

  – In 2010, lapatinib was also approved for use in combination with letrozole for the treatment of postmenopausal women with ER+ metastatic breast cancer that overexpresses HER2 and for whom hormonal therapy is indicated.

  – The most common adverse events associated with lapatinib are diarrhea, hand-foot syndrome, nausea, vomiting, fatigue, and rash distinct from hand-foot syndrome (Geyer et al, 2006).

• Neratinib is an irreversible tyrosine kinase inhibitor of HER1, HER2, and HER4 that has been investigated in a phase I/II trial in combination with capecitabine in patients with HER2+ mBC (Saura et al, 2014).

  – The most common drug-related AEs were diarrhea (88%) and palmar-plantar erythrodysesthesia syndrome (48%).

  – ORR was 64% in patients with no prior lapatinib exposure and 57% in patients previously treated with lapatinib; median PFS was 40.3 and 35.9 weeks, respectively.
C. mTOR Inhibitors

- mTOR inhibitors such as everolimus are hypothesized to reverse trastuzumab resistance via the hyperactivated PIK/ AKT/mTOR pathway due to PTEN loss, by sensitizing PTEN-deficient tumors to trastuzumab (Hurvitz et al, 2015).
- The phase III BOLERO-1 trial assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for 719 patients with HER2+ advanced BC (Hurvitz et al, 2015).
  - In the full population, median PFS was not statistically significant between the groups (14.95 months with everolimus vs 14.49 months with placebo).
  - The most common AEs were stomatitis (67% everolimus vs 32% placebo), diarrhea (57% vs 47%), and alopecia (47% vs 53%).
  - In the HR-negative, HER2+ subgroup, a 7.2-month prolongation in PFS was reported with the addition of everolimus, warranting further investigation.
- In the BOLERO-3 trial, everolimus added to trastuzumab and vinorelbine significantly improved PFS for patients with trastuzumab-resistant previously treated mBC (André et al, 2014).

D. Phosphatidylinositol-3-kinase (PI3K) Inhibitors

- Constitutive activation of the PI3K pathway has been proposed as a mechanism of trastuzumab resistance in HER2+ mBC (Jain et al, 2015).
- The PI3K inhibitor buparlisib (BKM120) was investigated in a phase Ib trial of 17 patients with HER2+ advanced/metastatic breast cancer resistant to trastuzumab-based therapy (Saura et al, 2014).
  - Common (>25%) adverse events included rash (39%), hyperglycemia (33%), and diarrhea (28%).
  - At the recommended phase II dose, there were two (17%) partial responses, 7 (58%) patients had stable disease (≥6 weeks), and the disease control rate was 75%.
- Alpelisib (BYL719), the first oral PI3K inhibitor that selectively inhibits the PI3K alpha isoform, was evaluated in combination with T-DM1 in 8 patients with trastuzumab-refractory HER2+ mBC (Jain et al, 2015).
  - The most common treatment-related AEs were fatigue (86%), nausea (75%), aspartate aminotransferase increase (50%), and thrombocytopenia (50%); grade 3 AEs were rash (n = 3), hyperglycemia (n=1), hypertension (n=1), and thrombocytopenia (n=1).
  - ORR was 86% (1 confirmed CR, 2 confirmed PRs, and 3 unconfirmed PRs).

E. Antibody-drug conjugates

- Ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate incorporating the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1, was approved in 2013 for use as a single agent for the treatment of patients with HER2-positive mBC who previously received treatment with trastuzumab and a taxane, separately or in combination.
  - In the pivotal trial of 991 patients treated with T-DM1 or lapatinib plus capecitabine, the median PFS was 9.6 months and 6.4 months, respectively; the median OS (30.9 vs. 25.1 months) and ORR (43.6%, vs. 30.8%) were also improved with T-DM1 (Verma et al, 2012).
  - Rates of grade 3-4 AEs were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%); the incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.
- MM-302, an antibody-drug conjugated HER2-targeted liposomal doxorubicin, was evaluated in a phase I trial of 69 heavily pre-treated patients administered MM-302 as monotherapy or in combination with trastuzumab or trastuzumab and cyclophosphamide (LoRusso et al, 2015).
  - Patients who received MM-302 plus trastuzumab had a median PFS of 7.6 months; those treated with the addition of cyclophosphamide had a median PFS of 10.6 months
  - Adverse events occurring in more than 20% of patients included constipation, cough, decreased appetite, diarrhea, dyspnea, fatigue, nausea, neutropenia, stomatitis, and vomiting.
  - The ongoing randomized phase 2 HERMIONE trial is comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline-naive HER2-positive, locally advanced/metastatic BC patients previously treated with pertuzumab and T-DM1.

II. NCCN Guidelines

Key NCCN guidelines for the treatment of HER2+ mBC are as follows (Gradishar et al, 2016):

- The identification of HER2 status in patients with mBC should be determined using fluorescence in situ hybridization and/or immunohistochemistry.
- Pertuzumab plus trastuzumab in combination with a taxane (docetaxel or paclitaxel) is the preferred option for first-line treatment of patients with HER2+ mBC; T-DM1 should be considered in patients not suitable for the preferred treatment, although published experience on the efficacy of T-DM1 after progression on trastuzumab/pertuzumab is limited.
- For patients with disease progression after treatment with trastuzumab-based therapy without pertuzumab, a line of therapy containing both trastuzumab plus pertuzumab with or without a cytotoxic agent (such as vinorelbine or taxane or an aromatase inhibitor for hormone receptor-positive tumors) may be considered; the regimen of capecitabine plus lapatinib is also an option.
References


Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc.

This activity is supported by an independent educational grant from Genentech BioOncology.